Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 9/20 | 0.48 |
| ▸ | CES1 | P23141 | 5/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MGAM | O43451 | 1/20 | 0.46 |
| ▸ | SI | P14410 | 1/20 | 0.46 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27897565 | 0.88 | FAAH (0.55) | FAAHCES1CES2CYP1A2MEN1 | |
| Succinic Acid Diethyl Ester SCHEMBL22780 | 0.81 | GAA (0.67) | CYP1A2HSD17B10GAAMGAMSI | |
| Succinic Acid Diethyl Ester SCHEMBL27768067 | 0.81 | GAA (0.67) | CYP1A2HSD17B10GAAMGAMSI | |
| SCHEMBL3955797 | 0.80 | CYP1A2 (0.48) | CYP1A2KMT2AHSD17B10GAAMGAM | |
| SCHEMBL77331 | 0.80 | GAA (0.61) | FAAHCES1CES2CYP1A2MEN1 | |
| SCHEMBL10172890 | 0.78 | CYP1A2 (0.47) | CYP1A2MEN1KMT2AHSD17B10GAA | |
| SCHEMBL3265478 | 0.78 | GAA (0.58) | FAAHCES1CES2CYP1A2MEN1 | |
| SCHEMBL7210415 | 0.78 | GAA (0.58) | FAAHCES1CES2CYP1A2MEN1 | |
| Water SCHEMBL10546276 | 0.78 | GAA (0.58) | FAAHCES1CES2CYP1A2MEN1 | |
| SCHEMBL7406648 | 0.78 | GAA (0.58) | FAAHCES1CES2CYP1A2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3898633-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Aktiengesellschaft (DE) | 2021-10-27 | — | — | EP | disclosed |
| CN-113474348-A | Substituted oxopyridine derivatives | 拜耳公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020127504-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-06-25 | — | — | WO | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742132-B2 | Indolylmaleimide derivatives processes for their production and pharmaceutical compositions | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-2094689-B1 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| CN-102766145-A | Fluorinated aza imidazolone derivative, synthesis method and application thereof | UNIV SHANGHAI | 2012-11-07 | — | — | CN | disclosed |
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG | 2012-08-30 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | NOVARTIS AG (CH) | 2010-02-18 | — | — | US | disclosed |
| EP-2094689-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008074752-A2 | INDOLYLMALEIMIDE DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
| CN-100357261-C | Ethyl 5,5,5-trifluoro-4-(1-naphthalenylimino)pentanoate and synthesis method thereof | UNIV SHANGHAI (CN) | 2007-12-26 | — | — | CN | disclosed |
| CN-1927825-A | Ethyl 5,5,5-trifluoro-4-(1-naphthalenylimino)pentanoate and synthesis method thereof | UNIV SHANGHAI (CN) | 2007-03-14 | — | — | CN | disclosed |
| CN-1107142-A | Hydrazine derivative and application of same | NIHON NOHYAKU CO LTD (JP) | 1995-08-23 | — | — | CN | disclosed |
| US-5064861-A | ACYLATED AMINE COMPOUNDS WHICH ARE USEFUL FUNGICIGAL AGENTS | ROUSSEL UCLAF (FR) | 1991-11-12 | — | — | US | disclosed |
| US-4326071-A | ENZYME INHIBITORS AND ANTIBIOTICS | MERRELL TORAUDE ET COMPAGNIE (FR) | 1982-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120219593-A1 | INDOLYLMALEIMIDE DERIVATIVES PROCESSES FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | RB1, INMT, IDH3A | FAAH 2767/4885CES1 1510/4885CES2 1823/4885 |
| US-20100041693-A1 | INDOLYLMALEIMIDE DERIVATIVES | IDH3A, IDH2, INMT | FAAH 2156/4885CES1 1322/4885CES2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.